Arecor Therapeutics (FRA:6UI) Institutional Ownership: 6.02% (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6UI Arecor Therapeutics PLC FRA:6UI
37 GF Score
Price €0.63
GF Value €0.45
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics Institutional Ownership?

Arecor Therapeutics FRA:6UI -3.08% 37 Institutional Ownership is 6.02% as of Aug. 01, 2026. GuruFocus rates FRA:6UI with a GF Score™ of 37/100 and a GF Value™ of €0.45. The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arecor Therapeutics's institutional ownership is 6.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arecor Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arecor Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

Arecor Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Arecor Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arecor Therapeutics Institutional Ownership Chart

Arecor Therapeutics Historical Data

The historical data trend for Arecor Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 7.41 7.08 6.02 6.02 6.02 6.02 6.02 6.02 6.02 6.02
FRA:6UI
37GF Score
Arecor Therapeutics PLC FRA:6UI
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arecor Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 6.02% mean?
Arecor Therapeutics (FRA:6UI) has a Institutional Ownership of 6.02% as of Aug. 01, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Arecor Therapeutics and its competitors.
Is Arecor Therapeutics' Institutional Ownership too high?
Arecor Therapeutics' current Institutional Ownership is 6.02%. Overall, Arecor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Institutional Ownership compare to VRTX and REGN?
Arecor Therapeutics' Institutional Ownership of 6.02% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Arecor Therapeutics and its competitors. Arecor Therapeutics's current Institutional Ownership is 6.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (FRA:6UI) has a current Institutional Ownership of 6.02%. The stock's GF Value™ is €0.45, compared to a current price of €0.63 — trading 40% above its estimated fair value. The current Institutional Ownership is 6.02%. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Arecor Therapeutics (FRA:6UI), the current Institutional Ownership is 6.02% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arecor Therapeutics (FRA:6UI) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of €0.63 is trading 40% above its estimated GF Value™ of €0.45.

Key valuation signals for FRA:6UI:

  • Institutional Ownership: 6.02%
  • GF Value™: €0.45 vs. price of €0.63 (40% above fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the FRA:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arecor Therapeutics Business Description

Other Exchanges AREC:UK6UI:Germany
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score

Get the complete analysis for FRA:6UI

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.63
Price
€0.45
GF Value